Streetbeat News

Earnings

TEVA

Teva Pharmaceutical has updated its 2024 adjusted EPS guidance to a range of $2.30-$2.50, up from the previous range of $2.20-$2.50, and above the consensus estimate of $2.34.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:08 am

SHOO

Steve Madden expects FY24 revenue to increase by 11% to 13% and adjusted EPS to be between $2.55 and $2.65, with an estimate of $2.64.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:07 am

SMG

Scotts Miracle-Gro shares are trading higher following better-than-expected Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:07 am

MAR

Marriott International has provided its forecast for the fiscal year 2024, projecting adjusted earnings per share (EPS) between $9.23 and $9.40, which is below the market estimate of $10.81.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:07 am

MAR

Marriott shares are trading lower after the company reported a Q2 revenue miss.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:06 am

LVO

LYV

MUSQ

Live Nation Entertainment Inc (LYV) reported mixed Q2 earnings, with EPS missing estimates but revenue slightly exceeding expectations. Despite economic challenges, Live Nation saw a 7% YoY revenue increase and a 21% rise in operating income. The MUSQ Global Music Industry ETF (MUSQ) offers diversified exposure to the music industry, including holdings in LYV and LiveOne Inc (LVO). MUSQ is currently trading near its 200-day moving average, presenting potential upside targets for investors.

Portfolio Pulse from Joshenomoto@benzinga.com

July 31, 2024 | 11:06 am

MAR

Marriott International has provided its Q3 2024 financial outlook, projecting gross fee revenues between $1.275 billion and $1.29 billion and adjusted EPS between $2.27 and $2.33, which is below the $2.38 estimate.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:06 am

TEVA

Teva Pharmaceutical has updated its 2024 revenue guidance to $16.0B-$16.4B, up from the previous $15.7B-$16.3B and above the consensus of $16.012B. Key product revenue projections have also been adjusted, with AUSTEDO expected to generate ~$1,600M, up from ~$1,500M, and COPAXONE expected to generate ~$450M, up from ~$400M. Other financial metrics such as operating income, adjusted EBITDA, and diluted EPS have seen slight improvements.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:06 am

DFIN

Donnelley Financial Solutions (NYSE:DFIN) reported Q2 earnings of $1.66 per share, beating the analyst estimate of $1.40. However, sales of $242.70 million missed the estimate of $244.62 million.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:05 am

OSK

Oshkosh Corporation has announced its FY24 adjusted EPS forecast of $11.75, surpassing the estimated $11.27.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:04 am